US FDA Warns of Rare Vision Loss Risk with Popular Diabetes and Weight-Loss Drugs

The U.S. Food and Drug Administration (FDA) announced Monday evening a requirement for new warnings on the labels of Ozempic, Wegovy, Mounjaro, and Zepbound, medications used to treat diabetes and obesity. This action stems from concerns about an increased risk of a rare vision impairment known as non-arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden, typically painless vision loss and, in some cases, irreversible damage.

The FDA's decision followed a review of clinical trials, observational studies, and post-market adverse event reports. While acknowledging the side effect is rare, the FDA stated that the warning does not revoke the drugs' approvals. Patients experiencing sudden vision decline are urged to seek immediate medical attention. They are also advised against discontinuing their regular treatment without consulting their physician.

In Israel, the "Amal" Association, representing diabetes specialist nurses, echoed the caution against self-discontinuation. "Based on available data, this is an extremely rare phenomenon, and a clear causal link between taking the medications and optic nerve damage has not yet been definitively established," said Sima Arbeli, the association's General Director. She emphasized that stopping treatment unsupervised poses a far greater and more immediate health risk.

The association recommends that concerned patients consult their medical team and see an ophthalmologist if they experience sudden vision changes. The article also touches on the growing popularity of weight-loss drugs, attributing it to a shift in medical perception of obesity as a complex metabolic condition rather than solely a lifestyle choice. These drugs work by influencing hormonal and metabolic mechanisms to reduce hunger and increase satiety, offering various administration methods.

However, the drugs can cause side effects like nausea, vomiting, diarrhea, and constipation, and are not suitable for everyone. Furthermore, weight lost may not be maintained after treatment cessation, necessitating personalized medical consideration and follow-up. As the market expands, comparisons between these medications should weigh not only weight loss efficacy but also safety, side effects, and treatment adherence.